Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT00298272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study was to evaluate the tolerability and safety of rituximab in combination with methotrexate (MTX) and etanercept or adalimumab in participants with active rheumatoid arthritis (RA). The secondary objective was to explore the efficacy of rituximab in combination with MTX and etanercept or adalimumab in participants with active RA.
Study identification
- NCT ID
- NCT00298272
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Interventions
- IDEC-C2B8 (rituximab) Biological
- Placebo Drug
- Methotrexate Drug
- Etanercept Drug
- Adalimumab Drug
- Methylprednisolone Drug
- Folate Dietary Supplement
Biological · Drug · Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Mar 31, 2009
- Completion
- Jun 30, 2011
- Last update posted
- Sep 27, 2015
2006 – 2011
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Huntsville | Alabama | 35801 | — |
| Research Site | Paradise Valley | Arizona | 85253 | — |
| Research Site | Palm Desert | California | 92260 | — |
| Research Site | Jupiter | Florida | 33458 | — |
| Research Site | Sarasota | Florida | 34239 | — |
| Research Site | Boise | Idaho | 83702 | — |
| Research Site | Kalamazoo | Michigan | 49048 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research site | Chardon | Ohio | 44024 | — |
| Research Site | Mayfield Village | Ohio | 44143 | — |
| Research Site | Oklahoma City | Oklahoma | 73103 | — |
| Research Site | Tulsa | Oklahoma | 74135 | — |
| Research Site | Duncansville | Pennsylvania | 16635 | — |
| Research Site | Dallas | Texas | 75231 | — |
| Research Site | Houston | Texas | 77074 | — |
| Research Site | San Antonio | Texas | 78217 | — |
| Research Site | Salt Lake City | Utah | 84132 | — |
| Research Site | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00298272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2015 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00298272 live on ClinicalTrials.gov.